Although it may seem like testing kits and other tools used in biomedical research have been around for ages, it is not the case. Much like a microscope, humans began by studying the human body as a whole, then moved to organs, then cells, and finally to the microscopic signaling pathways that dictate whether those cells behave or become pathological.
Among these findings, researchers relied on proteins that were used as signals, and at the heart of one of the most critical signaling intersections lies a protein known as PREX1 (Phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger 1).
However, it wasn’t instant that we found this and used it to its full potential. To study this protein effectively, researchers needed a tool that was both precise and accessible. This need led to the development of the PREX1 ELISA kit.
This blog will explore the origins of this essential laboratory resource and how companies like AAAbio have standardised the way we measure cellular movement.
The biological catalyst: Discovering PREX1
This goes without saying, but the story of the PREX1 ELISA kit begins not in a manufacturing plant. In the late 1990s and early 2000s, scientists were racing to understand how cells “crawl.” Cell motility is essential for life; white blood cells must move toward an infection, and skin cells must move to heal a wound. However, this same mechanism is hijacked by cancer cells to spread throughout the body.
Researchers identified a family of enzymes called Rho GTPases, specifically one called Rac1, which acts as the “motor” for cell movement. But much like a mechanical motor, Rac1 needs a starter as well. Scientists eventually discovered PREX1, a Guanine Nucleotide Exchange Factor (GEF) that acts as the specific switch to turn Rac1 on.
As the importance of PREX1 became clear—particularly its high expression in neutrophils (immune cells) and its over-expression in various cancers—the scientific community faced a hurdle. Identifying the presence of the protein was one thing, but quantifying it accurately across hundreds of samples was another.
The technological need: Why an ELISA?
Before the standardised PREX1 ELISA kit became available, researchers relied heavily on a method called Western Blotting. While effective for showing if a protein is present, Western Blotting is notoriously difficult to quantify, time-consuming, and prone to human error.
The need for the creation of the ELISA (Enzyme-Linked Immunosorbent Assay) format for PREX1 was rooted in three demands:
- Sensitivity: PREX1 often exists in trace amounts within complex biological fluids. Researchers needed a “hook” (an antibody) that could find the protein even in a crowded environment.
- Throughput: Clinical researchers studying breast cancer or melanoma needed to test dozens of patient samples simultaneously.
- Standardisation: For data to be peer-reviewed and validated, scientists needed a kit where the reagents were pre-tested, and the results were reproducible across different labs globally.
The clinical driving force: Cancer and immunology
The push to finalise and commercialise the PREX1 ELISA kit was largely driven by oncology. Research revealed that PREX1 is a major player in PI3K signaling, a pathway that is frequently mutated in cancer.
In breast cancer research, PREX1 was found to be a driver of metastasis. Doctors and researchers realised that if they could accurately measure PREX1 levels, they might be able to predict how aggressive a tumor might be. This transformed the kit from a basic “research tool” into a potential “biomarker tool.” If a researcher can use an AAAbio kit to show that a specific drug reduces PREX1 expression, they are one step closer to a cure.
Beyond cancer, the kit’s origins are tied to immunology. Because PREX1 controls the “respiratory burst” in white blood cells (how they kill bacteria), immunologists use these kits to study inflammatory diseases and autoimmune disorders.
